Physicians, NPs, PAs, pharmacists specializing in hematology, primary care, vascular surgery, and radiology involved in the care of patients with VTE

The treatment and management of venous thromboembolism (VTE) in patients with obesity or severe obesity can be a challenge. Join leading experts as they examine the latest efficacy and safety data from subgroup analyses of clinical trials and observational cohort studies in VTE treatment. Challenging case-based scenarios in this patient population will illustrate the application of new evidence into clinical practice.

Don't miss the opportunity to:

• Review NEW real-world data and hear expert discussion of insights from a VTE booster quiz for providers
• Hone your skills in clinical decision-making through complex case scenarios
• Engage in live Q&A with renowned experts in VTE

• Evaluate implications of current evidence on the safety and efficacy of direct oral anticoagulants (DOACs) from subgroup analyses of clinical trials and observational cohort studies on the management of patients with venous thromboembolism (VTE), including those who are severely obese
• Differentiate DOACs and conventional anticoagulants for the treatment of VTE in obese and severely obese patients based on clinical trial data regarding their efficacy and safety
• Apply the latest clinical data to evidence-based, patient-centered treatment decision-making regarding DOACs and conventional anticoagulants to optimize outcomes for obese patients with VTE
• Align clinical practices with evolving evidence and indications for appropriate integration of DOACs in the treatment and management of obese and severely obese patients

1. Addressing Challenges in Treating Obese and Severely Obese Patients With Venous Thromboembolism (VTE)
2. Beyond the Guidelines: Examining Evolving Clinical Evidence in VTE Treatment in Patients With Obesity
3. Expert Examination of the Safety and Efficacy Data of Direct Oral Anticoagulants (DOACs) and Conventional Anticoagulants
4. Developing Evidence-Based, Personalized Management Plans for Obese and Severely Obese Patients with VTE

1. Register using the online form
2. Complete the pre-registration survey
3. Attend the live program in its entirety
4. Complete an online evaluation and post-test
5. Download and/or print a certificate of completion and/or submit CE credits electronically

Instructions to access CME/CE credit options will be provided at the end of the program.

• Hardware: an Internet-enabled computer, smartphone, tablet, or mobile device with audio capabilities and Internet connectivity
• Software: the installation of software such as GoToWebinar may be required

*PRIME® has identified, reviewed, and mitigated all conflicts of interest that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity.

The following individuals have identified relevant financial relationships with commercial interests to disclose:

• Geoffrey D Barnes, MD, MSc (Speaker)
  
  Advisory Board or Panel – Janssen, Pfizer/Bristol Myers Squibb
  Consultant – Acelis Connected Health, Janssen, Pfizer/Bristol Myers Squibb
• Christian T Ruff, MD, MPH (Speaker)
  
  Advisory Board or Panel – Anthos, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Janssen, Pfizer, Portola
  Consultant – Anthos, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Janssen, Pfizer, Portola
  Grants / Research Support – Anthos, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, National Institutes of Health

The following individuals have no relevant financial relationships with commercial interests to disclose:

• Ali M Moran, DNP, AGACNP (Moderator)
• Henry A Solomon, MD, FACP, FACC (Reviewer)
• Joyce M Knestrick, PhD, CRNP, FAANP (Planner)
• Michele B Kaufman, PharmD, BCGP (Planner)

All PRIME® staff participating in planning and content development have no relevant financial relationships with commercial interests to disclose.